BRAF wild-type

P1, N=9, Not yet recruiting, West China Hospital

Interestingly, some of these patients may derive meaningful benefit from cytotoxic chemotherapy. We present the report of a case of a 63-year-old lady with BRAF wild type, locally advanced mucosal melanoma who demonstrated disease progression on combination immunotherapy with Ipilimumab and nivolumab. She subsequently achieved an exceptional and durable radiological and clinical response to chemotherapy with cisplatin and dacarbazine. This case highlights that, despite advances in personalized medicine and immunotherapy, conventional chemotherapy may still represent a valuable therapeutic option in selected patients, particularly in the refractory setting.

This study demonstrates significant alterations in the miRNA expression profile in metastatic melanoma and highlights the potential of miR-146a-5p and miR-4286 as key regulators of tumor biology.

Trastuzumab-based combinations and HER2-selective tyrosine kinase inhibitors such as tucatinib have demonstrated durable responses and favorable safety profiles in heavily pretreated patients. This review summarizes current evidence from pivotal phase II and III clinical trials, translational studies, and real-world data evaluating EGFR-, BRAF-, and HER2-directed therapies in colorectal cancer. Particular emphasis is placed on biomarker-guided patient selection, mechanisms of resistance, and emerging combination strategies that continue to refine precision oncology approaches in mCRC.

P1/2, N=117, Recruiting, Georgiamune Inc | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

This case highlights the crucial role of molecular profiling in the diagnostic workup of intramedullary melanocytic lesions. The identification of GNAQ mutations, after the exclusion of other GNAQ-mutated primaries, supports a primary CNS origin, whereas BRAF mutations suggest a metastatic origin. Accurate diagnosis drastically alters the oncological management.

P1/2, N=162, Recruiting, Association Gercor | Not yet recruiting --> Recruiting

The results indicate a worse overall prognosis for EO-CRC patients undergoing metastasectomy compared to average-onset patients. This outcome appears to occur independently of the molecular status. These observations could have a considerable impact on clinical practice and research.

P2, N=12, Not yet recruiting, M.D. Anderson Cancer Center

Our findings suggest significant clinical, pathologic, and molecular correlations in an Australian cohort of advanced melanoma treated with ICIs. Patients with NF1 mutation exhibited higher TMB, which was associated with improved response to ICIs.

P1, N=2, Active, not recruiting, Roswell Park Cancer Institute | Trial primary completion date: Jul 2025 --> Feb 2026

The overall survival rates were comparable between the RAS mutation emergence and persistent RAS wild-type groups (p = 0.88). In RAS wild-type mCRC, female patients and patients with high CEA levels may benefit from precision treatment strategies that incorporate real-time genetic monitoring.